Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin 7+3 vs Daunorubicin and Cytarabine Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and Daunorubicin and Cytarabine Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk Adverse Acute Myeloid Leukemia as Determined by MYELOMATCH; A MYELOMATCH CLINICAL TRIAL
Study Type: Treatment
Phase: II
NCTID: NCT05554406
Principal Investigator:
Tara Lin
Long-term follow-up protocol for subjects treated with gene-modified GM T-cells
Study Type: Treatment
Phase: III
NCTID: NCT03435796
Principal Investigator:
Al-Ola Abdallah
A Phase Ib, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
Study Type: Treatment
Phase: I/II
NCTID: NCT06433947
Principal Investigator:
Al-Ola Abdallah
A Measurable Residual Disease MRD Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
Study Type: Treatment
Phase: II
NCTID: NCT05554393
Principal Investigator:
Heather Male
A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase III Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid Immune Globulin Infusion, 10 for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen�CD3?Directed Bispecific Antibody Therapy
Study Type: Treatment
Phase: III
NCTID: NCT06980480
Principal Investigator:
Jenny Bhurtel
Master Screening and Reassessment Protocol MSRP for Tier Advancement in the NCI myeloMATCH Clinical Trials
Study Type: Screening
Phase: N/A
NCTID: NCT05564390
Principal Investigator:
Tara Lin
A Phase III, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation ASCT in Participants with Newly Diagnosed Multiple Myeloma NDMM
Study Type: Treatment
Phase: III
NCTID: NCT05827016
Principal Investigator:
Al-Ola Abdallah
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
Study Type: Treatment
Phase: II
NCTID: NCT06672146
Principal Investigator:
Kenneth Byrd
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone Dara-VCD Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Study Type: Treatment
Phase: III
NCTID: NCT06022939
Principal Investigator:
Muhammad Umair Mushtaq
Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Study Type: Supportive Care
Phase: IV
NCTID: NCT05201781
Principal Investigator:
Leyla Shune